In these populations, K-ras is the most commonly mutated oncogene in lung cancers in Western countries, with activating point mutations in 15%–20% of all patients of NSCLC [13,14] and 25%–35% of adenocarcinomas [15,16]. This evidence concerns the gene KRAS and lung cancer.